AmgenvsCapsoVision

AMGN and CV stock compared: price, dividend, valuation and results, from SEC filings.

AMGN

Amgen Inc.

$435.64

Value $235B

-0.72%
AMGN's page

CV

CapsoVision, Inc.

$6.11

Value $328M

-3.17%
CV's page

Amgen (AMGN) has a market value of $235B and CapsoVision (CV) $328M. Over the last year, with dividends, AMGN moved +31.5% and CV +14.6%. Dividend yield: AMGN 2.31%, CV none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    AMGN$235B

    CV$328M

    AMGN is 717 times CV

  • Revenue, 12 months

    AMGN$38.9B

    CV$14M

    AMGN is 2,795 times CV

  • Net income, 12 months

    AMGN$9.4B

    CV-$29M

  • Operating margin

    AMGN32.4%

    CV-212.1%

    244.5 points apart

  • ROIC

    AMGN16.2%

    CV-124.8%

    141.0 points apart

  • P/E

    AMGN25.0

    CV–

  • Dividend yield

    AMGN2.3%

    CV0.0%

    2.3 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

AMGN+31.5%

CV+14.6%

100150200250DecFebAprJunAugOct
Returns by period
PeriodAMGNWith dividendsCVWith dividends
1 year since November 19, 2025+31.5%Price +27.2%+14.6%Price +14.6%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

AMGNAmgenCVCapsoVision

Valuation

AMGNCV
Valuation
Price$435.64$6.11
Market value$235B$328M
Enterprise value (EV)$276B$328M
P/E25.0–
P/E, 5-year median23.0–
P/B16.412.4
EV/EBIT21.9–
Free cash flow yield4.1%–

Results and growth

AMGNCV
Results and growth
Revenue, 12 months$38.9B$14M
Net income, 12 months$9.4B-$29M
Free cash flow, 12 months$9.6B-$29M
Earnings per share, 12 months$17.25-$0.43
Revenue growth, year on year10.0%15.3%
Revenue growth a year, past+7.6%over 5 years+15.3%over 1 years
EPS growth a year, past+2.9%over 5 years–

Margins and returns on capital

AMGNCV
Margins and returns on capital
Gross margin70.9%49.7%
Operating margin32.4%-212.1%
Net margin24.1%-210.1%
ROIC16.2%-124.8%
ROE87.8%-156.5%

Balance sheet

AMGNCV
Balance sheet
Cash$13.2B–
Total debt$54.0B$780.0K
Net debt / EBITDA2.3–
Interest cover4.8×–

Dividends and buybacks

AMGNCV
Dividends and buybacks
Dividend yield2.3%–
Dividend per share, 12 months$10.08–
Dividend growth a year, past+8.1%over 5 years–
Buyback yield––
Shareholder yield2.3%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: AMGN or CV

Didn't find what you were looking for?

Ask us
Which is bigger, Amgen or CapsoVision?

By market value, Amgen ($235B) is about 716.9 times CapsoVision ($328M), at today's prices.

How did AMGN and CV stock do over the last 1 years?

Since November 19, 2025, AMGN's price moved +27.2% and CV's +14.6%. With dividends: AMGN +31.5% (+31.5% a year), CV +14.6% (+14.6% a year). Past returns do not predict future ones.

Which pays the higher dividend, AMGN or CV?

The dividend yield at today's price is 2.31% for Amgen and none for CapsoVision. Over the last twelve months they paid $10.08 and – per share.

Which has the higher profit margins, Amgen or CapsoVision?

Over the last twelve months, the net margin was 24.1% for Amgen and -210.1% for CapsoVision, and the operating margin 32.4% and -212.1%. Revenue was $38.9B and $14M.

Which is the better investment, Amgen or CapsoVision?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.